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Abstract
CRISPR-Cas9 represents a promising technology for genome editing, yet means of safe and 
efficient delivery remain to be fully realized. Here, we report a novel delivery vehicle to deliver 
the Cas9 protein and single-guide RNA simultaneously based on DNA nanoclews, yarn-like DNA 
nanoparticles synthesized by rolling circle amplification. The bio-inspired vehicles efficiently 
loaded Cas9/single-guide RNA complexes and delivered the complexes to the nuclei of human 
cells, allowing targeted gene disruptions while maintaining cell viability. Editing was most 
efficient when the DNA nanoclew sequence and the sgRNA guide sequence were partially 
complementary, offering a design rule for enhancing delivery. Overall, this strategy provides a 
versatile platform that could be adapted for delivering other DNA-binding proteins or for 
functional nucleic acids.
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CRISPR-Cas9 has rapidly transitioned from an RNA-directed defense system in prokaryotes 
to a facile genome-editing technology.[1] The editing merely requires the Cas9 nuclease and 
an engineered single-guide RNA (sgRNA): the 20-nucleotide guide portion of the sgRNA 
recognizes complementary DNA sequences flanked by a protospacer-adjacent motif (PAM), 
and Cas9 cleaves the recognized DNA.[2] The double-stranded break is then repaired 
through non-homologous end joining (NHEJ) or homology-directed repair (HDR), allowing 
defined alterations to the targeted region.[3]
As CRISPR-Cas9 systems undergo further development toward human therapeutics, 
delivery poses the major challenge. Cas9 and the sgRNA have been overwhelmingly 
encoded within the DNA of plasmids of viral vectors.[4] However, this DNA can randomly 
integrate into the genome, potentially giving rise to cancer or other genetic diseases.[5] 
Furthermore, the template-driven nature of gene expression limits control over the total 
amount of Cas9 protein and sgRNAs, where excess dosing has been attributed to off-target 
cleavage.[6] One alternative is to deliver the Cas9/sgRNA ribonucleotprotein complex,[7] 
which enables greater control over its intracellular concentration and limits the timeframe in 
which editing can occur. However, delivering protein and RNA remains a central challenge 
in drug delivery.[8] Most protein therapeutics, such as enzymes,[9] antibodies[10] or 
transcription factors,[11] suffer from low stability and poor cell membrane permeability as a 
result of their fragile tertiary structures and large molecular sizes.[8] The strong negative 
charges of RNA therapeutics, including siRNA or miRNA, blocks them from diffusing 
across cell membrane and their susceptibility to endonuclease often requires chemical 
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modification to prevent degradation.[12] Thus, devising an appropriate carrier to shield the 
protein and RNA from detrimental physiological environment and escort them 
simultaneously to cell nucleus is highly desirable.
Herein, we report a novel delivery vehicle for CRISPR-Cas9 based on biologically inspired 
yarn-like DNA nanoclew (NC) (Figure 1). The DNA NCs are synthesized by rolling circle 
amplification (RCA)[13] with palindromic sequences encoded to drive the self-assembly of 
nanoparticles. We previously demonstrated that the DNA NC could encapsulate the 
chemotherapeutic agent doxorubicin and drive its release based on environmental 
conditions.[14] Here, we hypothesized that the DNA NC can load and deliver the Cas9 
protein together with an sgRNA for genome editing. Inspired by the ability of single 
stranded DNA (ssDNA) to base pair with the guide portion of the Cas9-bound sgRNA,[15] 
we designed the DNA NC to be partially complementary to the sgRNA. Following loading 
of the DNA NC with the Cas9/sgRNA complex, we applied a coating of the cationic 
polymer polyethylenimine (PEI) to help induce endosomal escape.[16] The Cas9/sgRNA 
complex delivered to the cytoplasm could then be transported into the nucleus via nuclear-
localization-signal peptides fused to Cas9. We expected that the resulting delivery vehicle 
could form uniform particles and drive the formation of targeted insertions or deletions 
(indels) without measurable impact on cell viability.
To demonstrate the DNA NC-mediated delivery of CRISPR-Cas9, we first selected the well-
characterized and most extensively applied Streptococcus pyogenes Cas9.[17] Recombinant 
Cas9 fused with N-terminal and C-terminal nuclear localization signals[18] was purified 
following overexpression in Escherichia coli (Figure S1 in the SI) and incubated with one of 
two sgRNAs: one designed to target a sequence within the enhanced green fluorescent 
protein (EGFP) gene flanked by an NGG PAM, and the other control sgRNA (cgRNA) 
designed not to appreciably target any DNA sequence in EGFP or the human genome 
(Figure S2a). We confirmed that the resulting Cas9/sgRNA complex was active in vitro 
based on cleavage of a linearized plasmid encoding the EGFP gene, but only in the presence 
of Cas9 and the EGFP-targeting sgRNA (Figure S2b).
We next generated the DNA NC to bind the Cas9/sgRNA complex. The DNA template for 
RCA was designed to encode 12 nucleotides complementary to the 5’ end of the sgRNA 
(NC-12) along with the palindromic repeat that drives self-assembly (Table S1). The 
rationale was that the complementary sequence would promote base pairing between the 
DNA NC and the Cas9/sgRNA complex, thereby forming a strong but reversible interaction. 
To form the nanoparticle consisting of Cas9, sgRNA, NC-12, and PEI (Cas9/sgRNA/NC-12/
PEI), Cas9 and the sgRNA were incubated together, followed by the addition of the NC-12, 
and then the addition of PEI. Measuring the zeta potential at each assembly step showed that 
the positively charged Cas9 (+19.3 ± 3.8 mV) became negatively charged with the addition 
of sgRNA (−19.4 ± 3.7 mV) and then NC-12 (−28.6 ± 5 mV), which was reverted to 
positive charge upon the addition of PEI (+18.6 ± 4.1 mV) (Figure 2a, S3). Dynamic light 
scattering analysis (Figure 2b, S4), atomic force microscopy (Figure 2c, S4) and 
transmission electron microscopy (Figure 2d) revealed that the Cas9/sgRNA/NC-12/PEI 
nanoparticles were uniformly sized with a hydrodynamic size of ~56 nm. Interestingly, the 
fully assembled particle was more compact and uniformly sized than the NC-12 nanoclew 
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and the Cas9/sgRNA/NC-12 complex, potentially due to offsetting the dispersing charges. 
To assess the co-localization of each component, we applied confocal laser scanning 
microscopy (CLSM) to image nanoparticles comprised of Cas9 labeled with Alexa Fluor 
647 (AF647), the sgRNA, the NC-12 stained with Hoechst 33342, and PEI conjugated with 
FITC. Imaging revealed consistent co-localization of all dyes (Figure S5), confirming the 
stable assembly of Cas9/sgRNA/NC-12/PEI.
We further investigated the ability of the particles to deliver Cas9/sgRNA into cultured cells. 
As a model, we used an established U2OS cell line that constitutively expresses a 
destabilized form of EGFP (U2OS.EGFP).[6b] CLSM, a technique with depth selectivity for 
analyzing subcellular location of delivered drugs,[14, 19] was first applied to evaluate the 
localization of the Cas9/sgRNA/NC-12/PEI nanoparticles containing the AF647-labeled 
Cas9 (Figure 3a, S6). Over the course of six hours, the labeled Cas9 first binds to the cell 
surface, then enters the cytosol, and finally localizes to the nuclei as indicated by the 
colocalization of the red fluorescence signal from AF647-Cas9 with the blue fluorescent 
signal of stained nuclei. To elucidate the mechanism of internalization, we applied inhibitors 
of different endocytosis pathways[19b] and measured the relative uptake of the Cas9/sgRNA/
NC-12/PEI nanoparticles containing AF647-labeled Cas9. Flow cytometry analysis revealed 
that the inhibitors methyl-β-cyclodextrin (MCD) and amiloride (AMI) imparted the greatest 
reduction in Cas9 uptake (Figure 3b), suggesting that the particles were mainly internalized 
through lipid rafts and macropinocytosis.[19b] Furthermore, we evaluated the impact of the 
nanoparticles on cell viability. TO-PRO-3 live/dead assay[7a] demonstrated no measurable 
impact on viability even at high concentrations (200 nM) of Cas9 (Figure 3c).
Based on the evidence that the Cas9/sgRNA would reach cell nucleus, we next evaluated the 
extent to which Cas9/sgRNA could drive the formation of indels through targeted DNA 
cleavage and repair by the endogenous NHEJ pathway. By targeting the coding region of 
EGFP, most indels would shift the reading frame, thereby preventing proper EGFP 
expression. To evaluate the impact on EGFP expression, we incubated cells with the 
particles containing the EGFP-targeting sgRNA (Cas9/sgRNA/NC-12/PEI, Figure 4a) or the 
non-targeting cgRNA (Cas9/cgRNA/NC-12/PEI, Figure S7). Fluorescence microscopy and 
flow cytometry analysis revealed that the sgRNA reduced fluorescence in ~36% of the cells, 
whereas the cgRNA had a negligible effect in comparison to untreated cells. We also 
evaluated particles prepared with only Cas9, sgRNA, and PEI; these particles reduced 
fluorescence in only 5% of the cells, demonstrating the importance of the DNA NC for 
effective delivery. To assess whether the reduction in fluorescence was attributed to indel 
formation, we applied the SURVEYOR assay that quantifies the frequency of mutations 
within an amplified target region.[3] The assay revealed mutation frequencies of 28% and 
1.5% for cells treated with Cas9/sgRNA/NC-12/PEI and Cas9/sgRNA/PEI (Figure 4b), 
respectively, closely paralleling the flow cytometry analysis. We also subcloned the 
amplified target region of cells incubated with the Cas9/sgRNA/NC-12/PEI nanoparticles. 
Sanger sequencing of 20 clones revealed 7 clones with typical indels within the PAM or the 
sequence complementary to the sgRNA guide (Figure S7), confirming the genetic disruption 
of EGFP expression by CRISPR-Cas9.[3] One-time treatment with the DNA NC mediated 
Cas9/sgRNA delivery system lead to higher editing efficacy than the cell-penetrating 
peptides (CPPs) based vector (9.7%) if the variation of cell line and targeted locus were not 
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taken into account.[7b] Although the cationic lipid/anionic EGFP based delivery strategy 
showed higher editing efficacy (80%),[7a] lipid-vehicles are often hampered by serum 
instability, which could be alleviated by polymer-based carriers.[8, 20]
Then we asked how complementarity between the DNA NC and the sgRNA impacted the 
efficacy of Cas9-driven genome editing. To address this, we generated two additional 
variants of the DNA NC with 0 or 23 nucleotides complementary to the sgRNA (designated 
as NC-0 and NC-23, respectively). Agarose gel electrophoresis confirmed that NC-0 and 
NC-23 yielded similar molecular weight distributions as NC-12 and were resistant to Cas9/
sgRNA degradation (Figure S9). Subjecting the resulting particles to the U2OS.EGFP cells 
revealed that NC-12 yielded the highest fraction of EGFP negative cells (Figure 4c). This 
trend was upheld for different molar ratios of Cas9 and the sgRNA, where the 1:1 standard 
stoichiometry of the Cas9/sgRNA complex yielded the greatest activity. Altogether, these 
results suggest that partial complementarity between the sgRNA and the NC are important 
for efficient delivery, which may be attributed to the need for balancing Cas9/sgRNA 
loading and release.
We further evaluated the in vivo EGFP disruption potency of Cas9/sgRNA delivered by 
NC-12 using U2OS.EGFP tumor bearing mice as models. 10 days after intratumoral 
injection, ~25% the U2OS.EGFP cells in the frozen tumor sections near the site of injection 
lost EGFP expression in the Cas9/sgRNA/NC-12/PEI treated mice, while the tumors in the 
untreated group or the group treated with Cas9/cgRNA/NC-12/PEI did not show any loss of 
EGFP signal (Figure 5, S10).
In summary, we have demonstrated a novel delivery vehicle to achieve targeted genome 
editing with CRISPR-Cas9. Our DNA NC-based delivery system represents, to our 
knowledge, the first example of a polymeric nanoparticle for the delivery of CRISPR-Cas9. 
The DNA NC pre-organized the Cas9/sgRNA into nanoparticles and increased the charge 
densities of the core in the core-shell assembly, which may have acted to stabilize the 
nanoparticle.[7a, 21] Partial complementarity between the DNA nanoclew and the sgRNA 
guide sequence promoted the greatest extent of gene editing, potentially due to balancing 
binding and release of the Cas9/sgRNA complex by the nanoclew. Future implementation of 
the delivery vehicles may focus on attaching cell-specific targeting ligands,[22] engineering 
the environmentally responsive release of the CRISPR-Cas9,[14, 23] modifying the sequence 
of DNA NC to incorporate multiple sgRNAs for multiplexed editing, or employing the DNA 
NC or packaged DNA sequences as templates for homology-directed repair. The same NC 
architecture could also be used to incorporate other functional DNA-binding proteins, such 
as transcription factors, zinc-finger nucleases, and TALE nucleases, as well as other 
functional or protein-coding RNAs. The potential immunogenicity associated with DNA 
NCs should be further investigated for clinical translation.[24]
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Schematic design of the DNA NC mediated CRISPR-Cas9 delivery system. (a) Preparation 
of Cas9/sgRNA/NC/PEI. I: The NC was synthesized by RCA and loaded with the Cas9/
sgRNA complex through Watson-Crick base pairing; II: PEI was coated onto Cas9/
sgRNA/NC for enhanced endosome escape. (b) Delivery of Cas9/sgRNA by the DNA NC 
based carrier to the nucleus of the cell for genome editing. I: Bind to cell membrane; II: 
Endocytosis; III: Endosome escape; IV; Transport into the nucleus; V: Search for target 
DNA locus in the chromosome and introduce double strand breaks for genome editing.
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Particle characterization of Cas9/sgRNA/NC-12/PEI. (a) Monitoring zeta potential of the 
Cas9/sgRNA/NC-12/PEI assembly process. Bars represent mean ± SD (n = 3). (b) 
Hydrodynamic size distribution of Cas9/sgRNA/NC-12/PEI. (c) AFM image and d) TEM 
image of Cas9/sgRNA/NC-12/PEI with scale bars of 400 nm and 100 nm, respectively.
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a) CLSM images of U2OS.EGFP cells incubated with Cas9/sgRNA/NC-12/PEI for 1 h, 2 h, 
4 h and 6 h (Cas9 and sgRNA concentrations at 100 nM). Green for EGFP, red for Cas9 
stained with AF647 and blue for nuclei stained with Hoechst 33342. Scale bar is 10 µm. b) 
Relative Cas9/sgRNA/NC-12/PEI uptake by U2OS.EGFP cells in the presence of different 
endocytosis inhibitors (Cas9 and sgRNA concentrations at 100 nM). **P<0.01 as compared 
to the control group. Bars represent mean ± SD (n = 3). c) In vitro cell viability of 
U2OS.EGFP cells treated with Cas9/sgRNA/NC-12/PEI and Cas9/sgRNA/PEI by flow 
cytometry. The cells were stained with TO-PRO-3 live/dead stain after the treatment and 
analyzed by flow cytometry. Bars represent mean ± SD (n = 3).
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Genome editing by Cas9/sgRNA delivered by DNA NC (8 µg/mL) coated with PEI (10 µg/
mL). a) Fluorescent microscope images and flow cytometry analysis of U2OS.EGFP cells 
treated with Cas9/sgRNA/PEI and Cas9/sgRNA/NC-12/PEI (Cas9 and sgRNA 
concentrations at 100 nM). Green represents EGFP and blue represents nuclei stained with 
Hoechst 33342. Scale bar is 100 µm. b) T7EI assay of U2OS.EGFP cells treated with Cas9/
gRNA/NC-12/PEI and Cas9/gRNA/PEI. c) EGFP disruption assay of Cas9/gRNA delivered 
by different DNA NCs. Percentages of EGFP negative cells after treating with Cas9/sgRNA/
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NC-23/PEI, Cas9/sgRNA/NC-12/PEI, Cas9/sgRNA/NC-0/PEI and Cas9/sgRNA/PEI at 
different Cas9/sgRNA molar ratios were profiled. Bars represent mean ± SD (n = 3).
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In vivo delivery of Cas9/sgRNA into U2OS.EGFP xenograft tumors in nude mice. Tumor 
sections were collected 10 days after intratumoral injection of Cas9/sgRNA/NC-12/PEI. The 
EGFP was stained by FITC conjugated GFP antibody and nuclei were stained with Hoechst 
33342. Scale bar is 50 µm.
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